In vivo expression of angiostatin and endostatin, two different types of endothelial cell growth inhibitor, have been reported to inhibit vascularization in tumor tissues, resulting in tumor growth inhibition. Recently, in vivo expression of saxatilin, a novel disintegrin purified from snake (Gloydius saxatilis) venom, was able to strongly inhibit endothelial cell proliferation and smooth muscle cell migration, resulting in tumor growth inhibition. However, the antitumor efficacy of the individual antiangiogenic molecules expressed in vivo was not sufficiently potent to induce tumor regression in animal models. Therefore, in this study, we have systemically examined how combinational transfer of angiostatin, endostatin, and saxatilin genes affects neovascularization in tumor tissues and tumor progression in a mouse model. In Matrigel-implanted mice, cotransfection with plasmids encoding angiostatin K1-3 (pFLAG-Angio K1/3), endostatin (pFLAG-Endo), and saxatilin (pFLAG-Sax) resulted in the most effective inhibition of angiogenesis. In addition, hydrodynamic cotransfection of the three genes induced more inhibition of B16BL6 melanoma growth and pulmonary metastasis than other combinations of transfected genes. Compared with the empty vector-treated control group, cotreatment with the three plasmids reduced B16BL6 tumor growth by 89% and pulmonary metastasis by 90%. These results provide additional evidence supporting the combined systemic expression of antiangiogenic factors, such as angiostatin K1-3, endostatin, and saxatilin, as an alternative procedure for antiangiogenic cancer therapy.
Introduction
Angiogenesis, the growth of new microvasculature, is not only essential for a number of normal physiological processes, but also occurs in many pathological conditions including tumor growth. 1, 2 To promote angiogenesis, tumors regulate the production of various angiogenic factors, including fibroblast growth factor (FGF), vascular endothelial cell growth factor (VEGF), and vascular permeability factor (VPF). 3 In addition, for tumor progression, the expression of endogenous angiogenesis inhibitors must be simultaneously downregulated. 4 These observations provided a rationale for antiangiogenic therapy of cancer and suggested various therapeutic candidate molecules, such as angiostatin, endostatin, salmosin, and thrombospondin-1.
Recently angiostatin and endostatin have been extensively investigated for clinical applications in anticancer therapy. [5] [6] [7] Angiostatin K1-3 is a M r 35-kDa protein with a sequence identical to the first three triple-loop structures of plasminogen 8 and endostatin is a M r 20 000 COOHterminal fragment of collagen XVIII. 7 Unlike plasminogen and collagen XVII, angiostatin and endostatin exert their inhibitory effects on tumor progression via inhibition of endothelial proliferation. In tumor-bearing mice, administration of angiostatin and endostatin has been shown to inhibit virtually all neovascularization, resulting in some suppression of tumor progression. 6, 7 Saxatilin, a novel disintegrin purified from snake (Gloydius saxatilis) venom is a single-chain polypeptide composed of 73 amino acids including 12 cysteines as well as the tripeptide sequence Arg-Gly-Asp (RGD), a proposed recognition site for adhesive proteins. It has been reported that saxatilin strongly inhibits human platelet aggregation, endothelial cell proliferation and smooth muscle cell migration, thus inhibiting angiogenesis.
However, antiangiogenic cancer therapy with angiostatin, endostatin, or saxatilin is currently not clinically practical due to the requirement for high-dose administration of these proteins. 6, 7, 9 Also, due to their physical properties, it is difficult to produce these polypeptides in a functionally active form. [9] [10] [11] Therefore, instead of administration of the proteins themselves, in vivo transfer of saxatilin, angiostatin, or endostatin genes has been suggested as an alternative procedure to provide therapeutically effective levels of the functionally active proteins. 9, [12] [13] [14] Even though some trials of the antiangiogenic cancer gene therapy exhibited promising outcomes in animal models, there are still some gaps in reaching the goal of achieving significant tumor regression or remission.
In this study, simultaneous expression of angiostatin K1-3, endostatin, and saxatilin was achieved by systemic cotransfection of their genes using the hydrodynamic method, a newly developed convenient transfection procedure. 15 The antitumor efficacy of the coexpressed antiangiogenic proteins was assessed in a tumor-bearing mouse model. The results of the experiments presented in this report suggest that transfers of multiple antiangiogenic genes can provide an improved strategy for anticancer gene therapy.
Materials and methods
Cell lines, animals, and reagents B16BL6 melanoma cells were obtained from Dr Isaiah J Fidler (MD Anderson Cancer Center, University of Texas, Houston, TX). The cells were cultured in Eagle's medium supplemented with 5% fetal bovine serum (FBS), 1% nonessential amino acids, 2 mm glutamate, 1.5% vitamin solution, and 1% sodium pyruvate. Transformed human kidney cells (293 cells, ATCC: CRL-1573) were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% FBS and 1 mM sodium bicarbonate. The cells were grown at 371C in a humidified, 5% CO 2 atmosphere. C57BL/6 mice (6-to 8-week-old female and male; 20-24 g in weight) were used for in vivo tumor inoculation. DOTAP (1,2-dioleoyl-3-trimethylammonium propane) was purchased from Avanti Polar Lipids Inc. (Alabaster, AL). Cholesterol, anti-FLAG M2 monoclonal antibody, anti-FLAG M2 affinity gel, bFGF, and Drabkin reagent kit 529 were purchased from Sigma Chemical Co. (St Louis, MO). Matrigelt Basement Membrane Matrix was purchased from BD Biosciences (Bedford, MA). A blood vessel staining kit was purchased from Chemicon (Temecula, CA).
Constructs of pFLAG-AngioK1/3, pFLAG-Endo, and pFLAG-Sax The Construction of pFLAG-AngioK1/3, pFLAG-Endo, and pFLAG-Sax was detailed in the previous reports. 16, 17 Mouse angiostatin cDNA encoding the plasminogen amino acid residues 98-352 (Kringles 1-3, K1-3), was synthesized by a standard polymerase chain reaction (PCR) using the sense primer 5 0 -GGGGGTACCGTG TATCTGTCAGAATGTAAGACCG and the antisense primer 3 0 -GGGTCTAGAGCAGGATGGAATCTCA CAGTACTC. The PCR fragment was cloned into the pFLAG-CMV-1 vector (KODAK, New Haven, CT) and the construct designated as pFLAG-AngioK1/3. Mouse endostatin cDNA encoding the C-terminal 183 amino acids of collagen XVIII was also amplified by PCR using the sense primer 5 0 -GGGAAGCTTCATAC TCATCAGGACTTTCAGC and the antisense primer 3 0 -GGGGGATCCCTATTTGGAGAAAGAGGTCATG. The PCR fragment was cloned into the pFLAG-CMV-1 and this construct was designated as pFLAG-Endo. Saxatilin was also cloned into pFLAG-CMV-1 after PCR from a cDNA library of the Gloydius saxatilis venom gland using the sense primer 5 0 -GAGGCCGG AGAAGAATGTGACTGTGGC-3 0 and the antisense primer 5 0 -GGCATGGAAGGGATTTCTGGGACA-3 0 . The resulting construct was designated as pFLAG-Sax. The pFLAG-AngioK1/3, pFLAG-Endo, and pFLAGSax constructs were introduced into DH5a competent Eseherchia coli (Promega Inc., Madison, WI). The transformed cells were inoculated into LB broth for enrichment, the plasmids purified by the alkali lysis method 18 and then stored at À201C for further use.
In vivo gene expression For in vivo gene expression in mice, each plasmid was administered (i.v.) by the hydrodynamic method. 15 Four groups of 12 C57BL/6 mice were treated with rapid (5 s) injections of 20 mg of each plasmid (pFLAG-AngioK1/3, pFLAG-Endo, and pFLAG-Sax) in 2 ml saline. The mice were bled at 24 h and 1 week post-injection and the expressed angiostatin K1-3, endostatin, and saxatilin in their sera were purified by affinity chromatography using anti-FLAG M2 agarose.
Western blot analysis
The eluted solutions containing angiostatin K1-3 and endostatin were loaded on to 10% SDS-polyacrylamide gels, and those containing saxatilin were loaded on to a 10-20% SDS-polyacrylamide gel. After gel-shifting, the proteins in the gels were transferred to nitrocellulose membranes (Osmonics, Westborough, MA). The membranes were blocked with 5% skim milk in TBS (Trisbuffered saline) at 371C for 1 h and then incubated in an anti-FLAG M2 monoclonal antibody solution at room temperature for 2 h. The membranes were then incubated in the presence of goat anti-mouse IgG-horseradish peroxidase (HRP) conjugate (Upstate, Lake Placid, NY) at room temperature for 1 h. The immunoreactive bands were then stained by treatment of 3,3 0 -diaminobenzidine (DAB) (Sigma Chemical Co., St Louis, MO) solution.
Mouse matrigel plug assay. Matrigel (3.5 mg/400 ml, Becton-Dickinson, Bedford, MA) mixed with 0.2 mg of bFGF was injected into the abdominal region of individual 8-week-old C57BL/6 male mice. The mice were injected i.v. with various mixtures of plasmids (20 mg each plasmid in 2 ml) (pFLAG-AngioK1/3, pFLAGEndo, pFLAG-Sax, pFLAG-AngioK1/3 þ pFLAG-Endo, pFLAG-AngioK1-3 þ pFLAG-Sax, pFLAG-Endo þ pFLAG-Sax, and pFLAG-AngioK1-3 þ pFLAG-Endo þ pFLAG-Sax) by the hydrodynamic method 24 h post Matrigel administration. After 10 days, the Matrigel plugs were removed and photomicrographs were taken of the neo-blood vessels in the plugs. At the same time, hemoglobin concentrations in the Matrigel plugs were measured using a Drabkin kit 525 (Sigma, St Louis, MO) as described previously. 19 This assay was repeated twice.
Assay for inhibition of angiogenesis and tumor growth in Matrigel Matrigel containing 5 Â 10 4 B16BL6 tumor cells and 0.2 mg of bFGF was subcutaneously implanted onto the abdomen of C57BL/6 mice. These mice were treated with the plasmid mixtures as described in the mouse Matrigel plug assay. After 10 days, photomicrographs of the plugs were taken and hemoglobin concentrations in the Matrigel plugs were also measured. This assay was repeated twice.
Morphological and histopathological analysis of B16BL6 melanoma cells in Matrigel
The removed Matrigel plugs were fixed in 10% neutral, buffered formaldehyde for 24 h, then transferred into 80% ethanol and finally into 100% ethanol. The plugs were embedded in paraffin and sectioned following a standard histological procedure. The Matrigel sections (4 mm thick) were stained with hematoxylin and eosin, and examined with a microscope.
For blood vessel staining, the paraffin-embedded sections were deparaffinized, rehydrated, and then retrieved on a hotplate to recover tissue antigenicity. The retrieved sections were incubated in 0.5 mg/ml rabbit anti-vWF antibody (Chemicon, Temecula, CA) for 2 h. The primary antibody was detected using a Blood Vessel Staining Kit (Chemicon, Temecula, CA). The stained sections were examined with a microscope according to the method of Weidner. 20 The average of all of the fields examined within the hot spot area (MVD mean ) was recorded and expressed as counts/mm 2 .
Wound migration assay B16BL6 mouse melanoma cells (10 6 per well) were cultured in six-well tissue culture plates. After incubation for 40 h at 371C, the cells were treated with mitomycin C (25 mg/ml) for 30 min to inhibit proliferation. The cells were then injured (a line was scratched with a plastic scraper) and debris was removed by washing. Meanwhile, angiostatin K1-3, endostatin, and/or saxatilin genes were transfected to 293 transformed human kidney cells using the DOTAP/Chol lipoplex as described previously. 16 The culture medium containing angiostatin K1-3, endostatin, and/or saxatilin that had been expressed from the transfected 293 cells (0.5 ml) was added to the B16BL6 cells. The width of the injury line was observed microscopically at Â 40 magnification and the distance between the borders was measured (t 0 ) along the well. These experiments were performed in triplicate and the distance was measured at five fields in each well. After 24 h incubation at 371C, the distance between the borders in each field was measured again (t final ). Cell migration was calculated as the distance moved by the advancing cells of both borders.
Assay for inhibition of murine malignant tumor growth B16BL6 mouse melanoma cells (2 Â 10 5 ) were implanted subcutaneously into the back of 6-week-old female C57BL/6 mice (n ¼ 45) as previously described. 6 The tumors were measured in two dimensions using calipers every 7th day and their volumes were calculated as width 2 Â length Â 0.52. When the tumor volume (T/C) became approximately 100 mm 3 (0.5% of body weight), which normally occurred within 7 days post-implantation, the mice were randomized into nine treatment regimens (n ¼ 5): (a) saline; (b) pFLAG control (an empty vector); (c) pFLAG-AngioK1/3; (d) pFLAG-Endo; (e) pFLAG-Sax; (f) pFLAG-AngioK1/3 þ pFLAG-Endo; (g) pFLAG-AngioK1-3 þ pFLAG-Sax; (h) pFLAG-Endo þ pFLAG-Sax; and (i) pFLAG-AngioK1-3 þ pFLAGEndo þ pFLAG-Sax. The mice were injected i.v. every week by the hydrodynamic method with the appropriate regimen (20 mg DNA/2 ml saline).
Assay for inhibition of pulmonary metastasis
Implantation of tumor cells either by i.v. ('experimental') administration or subcutaneously (s.c.) ('spontaneous') implantation was used to induce tumor colony formation in mouse lungs. Experimental lung metastases were established in C57BL/6 mice by injection of 2 Â 10 4 B16BL6 cells in 0.1 ml of saline solution into the tail vein (n ¼ 5 per group). Every week post-tumor cell implantation, the mice were injected i.v. with various plasmid mixtures by the hydrodynamic method, as described previously in the mouse Matrigel plug assay. The mice were killed on day 28 and lung weights were measured.
For 'spontaneous' metastasis, B16BL6 cells (10 5 cells in 50 ml) were injected s.c. into the footpads of mice. After surgical removal of the primary tumors from these mice on day 21, they were treated as described for the experimental metastasis experiment. The mice were killed on day 40 and lung colonization was determined.
Statistical analysis
The statistical significance of the experimental results was analyzed by the Student's t-test. The difference between two mean values was considered as significant when the probability (P) was 0.05 or lower.
Results
In vivo expression of angiostatin K1-3, endostatin, and saxatilin genes The angiostatin K1-3, endostatin, or saxatilin genes were cloned individually into the pFLAG-CMV-1 plasmid, and the resulting constructs were named pFLAG-AngioK1/3, pFLAG-Endo, or pFLAG-Sax, respectively. In order to verify whether the gene products were able to be effectively expressed and circulate in an in vivo system, the prepared plasmids were administered into mice by the 'hydrodynamics-based transfection' method. Immunoblotting of sera collected from the transfected mice confirmed the gene-expression capability of the plasmid vectors (Figure 1 ). Mice treated with pFLAG-AngioK1/3 and pFLAG-Endo, or pFLAG-Sax all exhibited efficient expression of the respective genes; angiostatin K1-3 (40 kDa), endostatin (30 kDa), and saxatilin (7.7 kDa). Those expression was observed 1 week post-administration, but at a slightly diminished level (Figure 1, lane 4) , indicating that the gene expression could be sustained at least that long.
Inhibition of bFGF-induced angiogenesis in Matrigel
To verify that angiostatin K1-3, endostatin, and saxatilin expressed from the respective plasmids possessed antiangiogenic activity, the genes were administered into mice carrying Matrigel plugs impregnated with bFGF. Formation of functional vasculatures in the Matrigel plugs was determined by measuring the hemoglobin content in the plugs. 19 Hydrodynamic transfection of angiostatin K1-3, endostatin, and/or saxatilin genes resulted in remarkable inhibition of neovascularization, as indicated by reduced vessel infiltration and low hemoglobin content in the Matrigel plugs ( Figure 2 ). As expected, administration of multiple genes was also more effective than that of a single gene. Coadministration of pFLAG-AngioK1/3, pFLAG-Endo, and pFLAG-Sax was more effective in inhibition of neovascularization than coadministration of any other two-gene combinations. Similarly, instead of gene administration, addition of recombinant angiostatin K1-3, endostatin, and saxatilin to the Matrigel/bFGF mixture also inhibited angiogenesis in the Matrigel plugs more effectively than addition of two gene products in any combination (data not shown).
Inhibition of B16BL6-induced angiogenesis and tumor growth in Matrigel Analysis of angiogenesis using B16BL6 melanomaimpregnated Matrigel plugs was also used to evaluate Tumor inhibition by anti-angiogenic genes KS Kim et al inhibition of tumor-induced angiogenesis induced by transfection of the three genes. B16BL6 melanomaimpregnated Matrigel was implanted onto the abdomen of mice, which were then injected with various combinations of the plasmids. After 10 days, the individual Matrigels were removed and examined histologically (Figure 3a) . Angiogenesis induced by tumor cells was also the most significantly suppressed by coadministration of angiostatin K1-3, endostatin, and saxatilin genes. On the whole, the pattern of inhibition of angiogenesis induced by tumor cells was very similar to that induced by bFGF. . The hemoglobin content in the Matrigel plugs also exhibited a trend very similar to the measured microvessel density (Figure 3b ).
Effects of angiostatin K1-3 endostatin, and saxatilin on B16BL6 cell motility B16BL6 cell motility affected by angiostatin K1-3, endostatin, and saxatilin was determined by the wound migration assay. The B16BL6 tumor cells treated with angiostatin K1-3, endostatin, and/or saxatilin exhibited significantly reduced cell migration compared with untreated tumor cells (Figure 4 ). Even though it was not statistically significant, cotreatment with the three gene products appeared to be more effective in interfering with cell migration than other treatments.
Inhibition of B16BL6 tumor growth by administration of angiostatin K1-3, endostatin, and/or saxatilin genes B16BL6 mouse melanoma cells were implanted s.c. into the backs of C57BL/6 syngeneic mice which were then treated with angiostatin K1-3, endostatin, and/or saxatilin genes on every 7th day. During 25 days of observation, significant inhibition of the primary tumor growth was seen in all treated mice, with the tendency to tumor inhibition becoming apparent within a few days ( Figure 5 ). Coadministration of pFLAG-AngioK1/3, pFLAG-Endo, and pFLAG-Sax inhibited tumor growth more effectively than administration of any other combinations of these genes. The melanoma tumors in the saline-treated control group grew the most rapidly; developing up to a 45000 mm 3 Inhibition of pulmonary metastasis of B16BL6 tumor cells by angiostatin K1-3, endostatin, and saxatilin To investigate the effect of angiostatin K1-3, endostatin, and/or saxatilin on lung metastases of B16BL6 tumor cells, various combinations of the respective genes were injected administered i.v. to mice by the hydrodynamic method on every 7th day post-inoculation of tumor cells (experimental metastasis) or removal of primary tumors (spontaneous metastasis).
In the experimental metastasis assay, the mouse lungs were collected on day 28 post-tumor inoculation and the colonies of B16BL6 cells were determined. It was readily apparent that the mice cotreated with pFLAG-Angiok1-3, pFLAG-Endo, and pFALG-Sax had a fewer lung metastases than the other groups (Figure 6a) . Also, the mice treated with any two-gene combinations had a fewer colonies than those treated with a single gene. Since there were too many colonies to count, lung weights were measured to compare the pulmonary colonization among the treated mice. The lung weights of the mice cotreated with the three genes was significantly lower than those of mice treated with other combinations (Figure 6b ). In addition, treatment with angiostatin K1-3, endostatin, and saxatilin genes even more significantly affected survival of tumor-bearing mice. Eight out of 10 mice cotransfected with pFLAG-AngioK1-3, pFLAG-Endo, and pFLAG-Sax survived for over 55 days post-tumor inoculation while four mice cotreated with AngioK1-3/ pFLAG-Endo or pFLAG-Endo/pFLAG-Sax survived for the same time period (Figure 6c ). Mice treated with saline or a single gene survived for hardly 42 days. Therapeutic efficacies of cotransfected angiostatin K1-3, endostatin, and saxatilin genes were more readily discernible in the spontaneous metastasis experiment. The mice cotreated with pFLAG-AngioK1/3, pFLAG-Endo, and pFLAG-Sax exhibited the least lung colonization among the treated groups; a 90% reduction compared with the saline-treated control group (Figure 7 ). Mice treated with two genes or a single gene showed also significant reductions in pulmonary colonization, 84-88% and 71-80% reduction, respectively.
Discussion
It is widely accepted that inhibition of neovascularization in tumor tissues by antiangiogenic agents is a clinically applicable strategy for anticancer therapy. Among the antiangiogenic agents, endostatin has been clinically tested for anticancer therapy and angiostatin has been considered as another strong candidate for clinical trials. However, there are some requisites for successful antiangiogenesis cancer therapy, such as biologic half-life sufficient to sustain tumor suppression, accessibility into the tumor area, and lack of significant interference with normal angiogenesis processes. The administration of exogenous angiostatin or endostatin to treat cancers may not fulfill these requirements. As reported previously, 5, 7 delivery of exogenous angiostatin or endostatin into tumor areas in sufficient quantity and for a period sufficient to suppress tumor neovascularization is problematic. Saxatilin strongly inhibits tumor progression, but is subject to the same limitations. Hence, in vivo expression of the antiangiogenic genes has been suggested recently as an alternative strategy to exogenous protein administration.
The in vivo expression of exogenous genes by direct use of plasmid DNA was first reported by Wolf et al. 21 and demonstrated that a significant level of gene expression can be achieved in muscle cells by intramuscular injection of plasmid DNA. Following this initial discovery, many studies have reported success in expressing exogenous genes using regional administration. 22, 23 Recently, Liu et al.
15 also demonstrated that a high level of transgene expression can be achieved by systemic administration of plasmid DNA to mice by rapid injection of a large volume of DNA. Presumably, due to the unique anatomic structure of the liver and the hydrostatic pressure developed after this hydrodynamics-based procedure, hepatocytes may be able to uptake DNA efficiently and the liver becomes the main organ expressing the transgenes. In this research, the hydrodynamics-based transfection procedure was adopted to investigate the therapeutic efficacy of antiangiogenic proteins coexpressed in mice carrying tumors. The plasmids encoding angiostatin K1-3, endostatin, and/or saxatilin were administered to mice carrying B16BL6 melanoma and effects of antiangiogenic proteins on cancer development were investigated.
Administration of the plasmids encoding angiostatin K1-3 (pFLAG-AngioK1/3), endostatin (pFLAG-Endo) and/or saxatilin (pFLAG-Sax) genes was clearly effective in inhibition of cancer progression in mice. Repeated administration of angiostatin K1-3, endostatin and/or saxatilin genes significantly inhibited B16BL6 melanoma. Interestingly, coadministration of the three genes inhibited tumor growth more effectively than administration of two of these genes in any combination. Also, any combination of two of these genes exhibited more effective inhibition of tumor growth than treatment with a single gene. This implies that the three antiangiogenic proteins, simultaneously expressed in vivo and present together in the circulation, may function cooperatively (synergistically or additively) in inhibition of tumorinduced neovascularization. Similar cooperative actions were also seen in inhibition of pulmonary metastasis of B16BL6 cells. Mice repeatedly cotreated with the three genes exhibited the least lung colonization among the all treated groups. Less lung colonization was correlated with longer survival of the tumor-bearing mice. In all, 80% of mice cotreated with the three genes survived for over 55 days while only 20% of mice treated with angiostatin K1-3/endostatin or endostatin/saxatilin survived that long. The longer survival was due presumably to the fewer pulmonary metastases resulting from more effective inhibition of tumor neovascularization by simultaneously expressed angiostatin K1-3, endostatin, and saxatilin.
Previously, we proposed that coexpressed angiostatin and endostatin may work together to inhibit in vivo cancer growth and metastasis. 16, 24 In this report, inhibition of in vivo angiogenesis in Matrigel containing tumor cells by the three antiangiogenic proteins provided more conclusive evidence to support their synergistic (or additive) antineovascularization activity. The mechanical explanation for the enhanced inhibition of angiogenesis by the three different components is, as yet, not completely clear. However, it can be speculated that the observed synergistic (or additive) effect on tumor progression may be due to their nonoverlapping antiangiogenic mechanisms. The potential synergism of these three antiangiogenic agents will be better understood when the downstream effectors of these three molecules are further described. Recently, it was reported that reduction of Bcl-2 and Bcl-X L is observed in endostatin-mediated apoptosis and that tyrosine kinase activity via the Shb adaptor protein induced by endostatin is critical to the regulation of endothelial cell apoptosis. 11, 25 Meanwhile, angiostatin has been shown to inhibit endothelial cell proliferation by binding the a/b subunits of a membranebound ATP synthase 26 and downregulating cell cycle regulatory proteins such as the M-phase phosphoproteins. 27 In case of saxatilin, it has been reported to interfere with the binding of integrin glycoprotein II b-III a and a v b 3 on the surface of endothelial cells to the extracellular matrix, 17 resulting in failure of these cells to migrate and form capillary tubes. Therefore, it is conceivable that, if the cotransfected genes are efficiently expressed in vivo, certain cooperative actions derived from the nonoverlapping natures of their antiangiogenic mechanisms could result in synergistic inhibition of neovascularization, thus impeding tumor growth and metastasis.
This report suggests that inhibition of endothelial cell proliferation and migration via different mechanistic activities may produce a better outcome. In summary, angiostatin K1-3, endostatin, and saxatilin were effectively expressed by systemic administration of their genes and were therapeutically accessible to the experimental tumor areas. In a mouse model, the simultaneously expressed gene products were more effective in inhibition of angiogenesis and more efficiently suppressing tumor progression than the individually expressed genes. Development of an efficient, systemic, nonviral genetransfer procedure applicable to larger animals will make it possible to further evaluate the potential clinical applications of combinational antiangiogenic cancer gene therapy with angiostatin K1-3, endostatin, and saxatilin genes.
